TABLE 2

The effect of extracellular αKG (5 μM) on potency of OAT1 inhibition

Data are mean ± S.D. of four to six experiments. Significant differences in IC₅₀ values (between control and +5 μM αKG) was determined by unpaired Student’s t test.

	IC₅₀ against PAH			IC₅₀ against Cidofovir
Inhibitor	Control	+5 μM αKG	Fold Change	Control	+5 μM αKG	Fold Change
	μM
Probenecid	10.5 ± 1.9	24.3 ± 8.3^*	2.3	7.63 ± 3.5	14.8 ± 3.9^*	1.9
Indomethacin	3.79 ± 1.9	9.50 ± 2.6^*	2.5	ND	ND
Naproxen	2.23 ± 1.3	5.22 ± 2.0^*	2.3	2.05 ± 0.6	5.22 ± 2.4^*	2.5
Ibuprofen	3.08 ± 1.2	12.2 ± 2.9**	4.0	ND	ND
Furosemide	17.8 ± 6.1	21.3 ± 9.2	1.2	9.67 ± 4.7	24.1 ± 13^*	2.5
Bumetanide	11.9 ± 3.0	23.3 ± 10^*	1.9	ND	ND
Valsartan	8.0 ± 1.7	10.4 ± 1.6	1.3	4.93 ± 1.2	9.21 ± 3.60^*	1.9
Telmisartan	0.33 ± 0.10	0.35 ± 0.16	1.0	ND	ND
Cephalothin	283 ± 30	789 ± 140***	2.8	397 ± 88	972 ± 393^*	2.4
Ceftriaxone	391 ± 134	958 ± 99.7**	2.4	ND	ND

ND, not determined.
↵* P < 0.05; **P < 0.01; ***P < 0.001.